journal
MENU ▼
Read by QxMD icon Read
search

Clinical Lung Cancer

journal
https://www.readbyqxmd.com/read/29338938/distinct-met-protein-localization-associated-with-met-exon-14-mutation-types-in-patients-with-non-small-cell-lung-cancer
#1
Tian Qiu, Weihua Li, Tongtong Zhang, Puyuan Xing, Wenting Huang, Bingning Wang, Lixia Chu, Lei Guo, Xiuyun Liu, Yan Li, Jianming Ying, Junling Li
BACKGROUND: The MET gene has been recognized as a potential important therapeutic target in non-small-cell lung cancer (NSCLC). We sought to investigate the MET exon 14 mutations in a cohort of Chinese patients with NSCLC. METHODS: We tested 461 NSCLCs for MET exon 14 mutations by sequencing whole exon 14 and its flanking introns. The protein expression was determined by immunohistochemical analysis. RESULTS: In this study, we identified MET exon 14 mutations in 9 (2...
December 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29336998/developing-a-predictive-model-for-clinical-outcomes-of-advanced-non-small-cell-lung-cancer-patients-treated-with-nivolumab
#2
Wungki Park, Deukwoo Kwon, Diana Saravia, Amrita Desai, Fernando Vargas, Mohamed El Dinali, Jessica Warsch, Roy Elias, Young Kwang Chae, Dae Won Kim, Sean Warsch, Adrian Ishkanian, Chukwuemeka Ikpeazu, Raja Mudad, Gilberto Lopes, Mohammad Jahanzeb
INTRODUCTION: Despite significant improvement of clinical outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immunotherapy, our knowledge of optimal biomarkers is still limited. PATIENTS AND METHODS: We retrospectively evaluated 159 advanced NSCLC patients in our institution treated with nivolumab after disease progression during platinum-based chemotherapy. We correlated several variables with progression-free survival (PFS) to develop the immunotherapy, Sex, Eastern Cooperative Oncology Group performance status, Neutrophil-to-lymphocyte ratio (NLR), and Delta NLR (iSEND) model...
December 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29329944/use-of-superarms-egfr-mutation-detection-kit-to-detect-egfr-in-plasma-cell-free-dna-of-patients-with-lung-adenocarcinoma
#3
Shaohua Cui, Lin Ye, Huimin Wang, Tianqing Chu, Yizhuo Zhao, Aiqin Gu, Liwen Xiong, Chunlei Shi, Liyan Jiang
BACKGROUND: The SuperARMS EGFR Mutation Detection Kit (SuperARMS) is highly selective and sensitive and able to detect 41 of the most common somatic mutations in exons 18 to 21 of the epidermal growth factor receptor gene (EGFR). It allows for the detection of 0.2% to 0.8% mutant DNA in a background of 99.8% to 99.2% normal DNA. The present study assessed the performance of SuperARMS in detecting EGFR mutations in cell-free DNA (cfDNA) samples derived from plasma in patients with advanced lung adenocarcinoma...
December 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29307591/radiologic-pathologic-correlation-of-solid-portions-on-thin-section-ct-images-in-lung-adenocarcinoma-a-multicenter-study
#4
Masahiro Yanagawa, Masahiko Kusumoto, Takeshi Johkoh, Masayuki Noguchi, Yuko Minami, Fumikazu Sakai, Hisao Asamura, Noriyuki Tomiyama
BACKGROUND: Measuring the size of invasiveness on computed tomography (CT) for the T descriptor size was deemed important in the 8th edition of the TNM lung cancer classification. We aimed to correlate the maximal dimensions of the solid portions using both lung and mediastinal window settings on CT imaging with the pathologic invasiveness (> 0.5 cm) in lung adenocarcinoma patients. MATERIALS AND METHODS: The study population consisted of 378 patients with a histologic diagnosis of adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (IVA)-lepidic, IVA-acinar and/or IVA-papillary, and IVA-micropapillary and/or solid adenocarcinoma...
December 19, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29277564/feasibility-of-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-cytology-specimens-for-next-generation-sequencing-in-non-small-cell-lung-cancer
#5
Sean P Stoy, Jeremy P Segal, Jeffrey Mueller, Larissa V Furtado, Everett E Vokes, Jyoti D Patel, Septimiu Murgu
INTRODUCTION: Next generation sequencing (NGS) testing of lung cancer is recommended by guidelines, and endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) often provides the only material available for testing. Previous studies have demonstrated successful NGS testing on cell block samples obtained by EBUS; however, cytology smears provide a more reliable sample with better DNA quality for testing. In this study, we aimed to determine the success rate of OncoScreen (50 gene) and OncoPlus (1213 gene) panel NGS testing of cytology samples obtained by EBUS utilizing 22- and 25-gauge needles...
December 5, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29275041/utility-of-maximum-standard-uptake-value-as-a-predictor-for-differentiating-the-invasiveness-of-t1-stage-pulmonary-adenocarcinoma
#6
Lilan Fu, Mohammed Shah Alam, Yunyan Ren, Wei Guan, Hubing Wu, Quanshi Wang, Yanjiang Han, Wenlan Zhou, Hongsheng Li, Zhen Wang
BACKGROUND: The present study was performed to investigate the maximum standardized uptake value (SUVmax) in 2-[fluorine-18]-fluoro-2-deoxy-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) to preoperatively distinguish invasive from less-invasive pulmonary adenocarcinoma. PATIENTS AND METHODS: A total of 106 patients with resectable pulmonary adenocarcinoma (≤ 3 cm) who had undergone whole-body 18F-FDG PET/CT were enrolled. The SUVmax, diameter, and consolidation/tumor (C/T) ratio of the lung tumors were measured with 18F-FDG PET/CT and regional thin-section CT...
December 2, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29277565/pilot-study-of-the-safety-and-efficacy-of-dose-escalation-in-stereotactic-body-radiotherapy-for-peripheral-lung-tumors
#7
Takamasa Mitsuyoshi, Yukinori Matsuo, Takashi Shintani, Yusuke Iizuka, Nami Ueki, Mitsuhiro Nakamura, Takashi Mizowaki
BACKGROUND: This pilot study aimed to evaluate the safety and efficacy of a dose escalation method for the treatment of peripheral lung tumors by administrating steep dose gradients in the target volumes via stereotactic body radiotherapy (SBRT). PATIENTS AND METHODS: Patients with peripheral lung tumors were enrolled onto this study and treated with SBRT using a total dose of 70 Gy in 4 fractions at target isocenter, covering the planning target volume surface with 70% of the isodose...
November 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29254649/three-versus-five-fraction-regimens-of-stereotactic-body-radiotherapy-for-peripheral-early-stage-non-small-cell-lung-cancer-a-two-institution-propensity-score-matched-analysis
#8
Sung Jun Ma, Michael Cummings, Lucas M Serra, Yusef A Syed, Gregory M Hermann, Yuhchyau Chen, Michael T Milano, Anurag K Singh, Jorge A Gomez-Suescun, Deepinder P Singh
PURPOSE: To evaluate differences in outcomes of early-stage peripheral non-small-cell lung cancer (NSCLC) treated with either 3- or 5-fraction stereotactic body radiotherapy (SBRT) at 2 institutions. PATIENTS AND METHODS: Patients diagnosed with peripherally located early-stage NSCLC who received either a median dose of 60 Gy (interquartile range [IQR], 60-60, biologically effective dose, 151-151) in 3 fractions or a median dose of 50 Gy (IQR, 50-50, biologically effective dose, 94-94) in 5 fractions were included in this study...
November 26, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29317191/randomized-double-blind-phase-ib-iii-study-of-erlotinib-with-ramucirumab-or-placebo-in-previously-untreated-egfr-mutant-metastatic-non-small-cell-lung-cancer-relay-phase-ib-results
#9
Martin Reck, Edward B Garon, Luis Paz-Ares, Santiago Ponce, Jesus Corral Jaime, Oscar Juan, Ernest Nadal, Katsuyuki Kiura, Ryan C Widau, Shuang He, Rita Dalal, Pablo Lee, Kazuhiko Nakagawa
BACKGROUND: Despite the likelihood of an initial response to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer (NSCLC) patients develop disease progression. Antiangiogenic agents in combination with an EGFR TKI might provide additional benefit in patients with EGFR-mutant NSCLC. In this article we report safety, exposure, and progression-free survival (PFS) results for part A (phase Ib) of RELAY, a randomized, double-blind, phase Ib/III study investigating safety and efficacy of erlotinib (EGFR TKI) with ramucirumab (anti-vascular endothelial growth factor receptor-2 antibody) or placebo in first-line EGFR-mutant stage IV NSCLC...
November 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29221762/continuous-infusion-of-cilengitide-plus-chemoradiotherapy-for-patients-with-stage-iii-non-small-cell-lung-cancer-a-phase-i-study
#10
Carole Massabeau, Jonathan Khalifa, Thomas Filleron, Anouchka Modesto, Laurence Bigay-Gamé, Gavin Plat, Lawrence Dierickx, Richard Aziza, Isabelle Rouquette, Carlos Gomez-Roca, Muriel Mounier, Jean-Pierre Delord, Christine Toulas, Pascale Olivier, Etienne Chatelut, Julien Mazières, Elizabeth Cohen-Jonathan Moyal
INTRODUCTION: Because of our previous preclinical results, we conducted a phase I study associating the specific αvβ3/αvβ5 integrin inhibitor cilengitide, given as a continuous infusion, with exclusive chemoradiotherapy for patients with stage III non-small-cell lung cancer. PATIENTS AND METHODS: A standard 3+3 dose escalation design was used. Cilengitide was given as a continuous infusion (dose levels of 12, 18, 27, and 40 mg/h), starting 2 weeks before and continuing for the whole course of chemoradiotherapy (66 Gy combined with platinum/vinorelbine), and then at a dose of 2000 mg twice weekly in association with chemotherapy...
November 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29208356/practice-patterns-and-outcomes-in-elderly-stage-i-non-small-cell-lung-cancer-a-2004-to-2012-seer-analysis
#11
Shraddha M Dalwadi, Sean S Szeja, Eric H Bernicker, E Brian Butler, Bin S Teh, Andrew M Farach
BACKGROUND: We reviewed the population-based treatment patterns and outcomes for elderly patients with stage I non-small-cell lung cancer (NSCLC) treated from 2004 to 2012. PATIENTS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified biopsy-proven stage I NSCLC cases diagnosed from 2004 to 2012. The patients were divided into 5-year age subsets (60-64, 65-69, 70-74, 75-79, 80-84, 85-89, and ≥ 90 years). The demographic data, therapy, and survival were compared by year...
November 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29208355/usage-of-prophylactic-cranial-irradiation-in-elderly-patients-with-small-cell-lung-cancer
#12
Ronald A M Damhuis, Suresh Senan, Jose S Belderbos
BACKGROUND: Prophylactic cranial irradiation (PCI) reduces the risk of overt brain metastases in patients with small-cell lung cancer (SCLC) and is currently recommended in guidelines for both limited and extensive disease. Given the concerns about the greater frequency of neurologic side effects in elderly patients, we studied the association among age, PCI usage, and survival for SCLC patients in the Netherlands. PATIENTS AND METHODS: Data from the Netherlands Cancer Registry for patients diagnosed with SCLC from 2009 to 2013 were queried...
November 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29158124/improved-survival-with-increased-time-to-radiation-and-sequential-chemotherapy-after-surgery-for-pn2-non-small-cell-lung-cancer
#13
Karna Sura, Inga S Grills, Charles C Vu, Craig W Stevens, Hong Ye, Thomas M Guerrero
BACKGROUND: Currently, the ideal timing for postoperative radiotherapy (PORT) and chemotherapy is unknown. The present study evaluated their relative timing on overall survival (OS) using the National Cancer Database (NCDB). MATERIALS AND METHODS: The NCDB was queried for patients from 2004 to 2012 with resected non-small-cell lung cancer (NSCLC), pathologically involved N2 (pN2) nodes, and negative margins. All patients underwent adjuvant chemotherapy and external beam radiotherapy...
November 17, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29196082/feasible-optimization-of-stereotactic-ablative-radiotherapy-dose-by-tumor-size-for-stage-i-non-small-cell-lung-cancer
#14
Sumin Lee, Si Yeol Song, Su Ssan Kim, Wonsik Choi, Hyoung Uk Je, Geum Mun Back, Byungchul Cho, Seong-Yun Jeong, Eun Kyung Choi
INTRODUCTION: The purpose of this study was to assess the effect of dose escalation of stereotactic ablative radiotherapy (SABR) by investigating the long-term clinical outcomes of SABR for stage I non-small-cell lung cancer (NSCLC). METHODS: A retrospective analysis was performed on a total of 169 patients with 178 lesions of stage I NSCLC treated with SABR at a single institution from June 2000 to May 2015. The standard dose scheme for SABR was 48 Gy in 4 fractions during the early period of the analysis, but it was escalated to 60 Gy in 4 fractions from June 2009...
November 14, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29175386/impact-of-clinicopathologic-features-on-the-efficacy-of-pd-1-pd-l1-inhibitors-in-patients-with-previously-treated-non-small-cell-lung-cancer
#15
Tao Jiang, Hongcheng Liu, Meng Qiao, Xuefei Li, Chao Zhao, Chunxia Su, Shengxiang Ren, Caicun Zhou
BACKGROUND: The current study aimed to comprehensively investigate the impact of various clinicopathologic features on the efficacy of programmed cell death-1 (PD-1) and ligand (PD-L1) inhibitors in patients with previously treated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Randomized controlled trials that compared PD-1/PD-L1-inhibitor monotherapy with chemotherapy or placebo in patients with previously treated NSCLC were included. RESULTS: Five trials were included (n = 3025)...
November 9, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29233611/analysis-of-factors-associated-with-in-hospital-mortality-in-lung-cancer-chemotherapy-patients-with-neutropenia
#16
REVIEW
Julia Cupp, Eva Culakova, Marek S Poniewierski, David C Dale, Gary H Lyman, Jeffrey Crawford
Lung cancer, compared with other solid tumors, is associated with high mortality rates from febrile neutropenia. The risk factors associated with in-hospital mortality were identified and compared for patients with lung cancer and patients with other solid tumors. Hospitalization data from the University Health Consortium database inclusive of 2004 to 2012 were analyzed. The study population included all adult patients with solid tumors who developed neutropenia. Cancer type, the presence of neutropenia, and further subgroups were determined using International Classification of Diseases, 9th revision, Clinical Modification codes...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29174221/lung-toxicity-in-non-small-cell-lung-cancer-patients-exposed-to-alk-inhibitors-report-of-a-peculiar-case-and-systematic-review-of-the-literature
#17
REVIEW
Benedetta Pellegrino, Francesco Facchinetti, Paola Bordi, Mario Silva, Letizia Gnetti, Marcello Tiseo
Lung toxicity is a potential fatal effect involving non-small-cell lung cancer (NSCLC) patients exposed to tyrosine kinase inhibitors (TKIs). Moving from our experience regarding a patient who developed lung toxicity while receiving 2 different anaplastic lymphoma kinase (ALK)-TKIs, we performed a systematic review to assess the epidemiologic magnitude and the clinical significance of such toxicity in NSCLC patients treated with ALK-TKIs. Studies were identified using MEDLINE and additional sources (European Society for Medical Oncology, American Society of Clinical Oncology, and World Conference on Lung Cancer abstracts) in agreement with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane guidelines...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29174086/utility-of-liquid-biopsy-by-improved-pna-lna-pcr-clamp-method-for-detecting-egfr-mutation-at-initial-diagnosis-of-non-small-cell-lung-cancer-observational-study-of-190-consecutive-cases-in-clinical-practice
#18
Kentaro Ito, Yuta Suzuki, Haruko Saiki, Tadashi Sakaguchi, Kosuke Hayashi, Yoichi Nishii, Fumiaki Watanabe, Osamu Hataji
BACKGROUND: The clinical benefit of liquid biopsy for unselected patients at initial diagnosis has thus far been unclear. We aimed to evaluate the utility of liquid biopsy at initial diagnosis, as well as the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) based on liquid biopsy results in clinical practice, using the improved peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp method. PATIENTS AND METHODS: We routinely performed liquid biopsy using the improved PNA-LNA PCR clamp method for all patients diagnosed with non-small-cell lung cancer (NSCLC) between June 2015 and October 2016...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29153968/effect-of-contract-research-organization-bureaucracy-in-clinical-trial-management-a%C3%A2-model-from-lung-cancer
#19
Elisa Gobbini, Sara Pilotto, Giulia Pasello, Valentina Polo, Massimo Di Maio, Francesca Arizio, Domenico Galetta, Patrizia Petrillo, Rita Chiari, Roberta Matocci, Alessandro Di Costanzo, Teresa Severina Di Stefano, Massimo Aglietta, Celeste Cagnazzo, Isabella Sperduti, Emilio Bria, Silvia Novello
INTRODUCTION: Contract research organization (CRO) support is largely included in clinical trial management, although its effect in terms of time savings and benefit has not yet been quantified. We performed a retrospective multicenter analysis of lung cancer trials to explore differences in term of trial activation timelines and accrual for studies with and without CRO involvement. MATERIALS AND METHODS: Results regarding study timelines from feasibility data to first patient enrollment were collected from 7 Italian thoracic oncology departments...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29153966/nomogram-to-predict-cause-specific-mortality-in-patients-with-surgically-resected-stage-i-non-small-cell-lung-cancer-a-competing-risk-analysis
#20
Huaqiang Zhou, Yaxiong Zhang, Zeting Qiu, Gang Chen, Shaodong Hong, Xi Chen, Zhonghan Zhang, Yan Huang, Li Zhang
BACKGROUND: The objective of this study was to evaluate the probability of cause-specific death and other causes of death in patients with stage I non-small-cell lung cancer (NSCLC) who underwent surgery. We also built competing risk nomograms to predict the prognosis of patients with NSCLC. PATIENTS AND METHODS: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. We identified patients who underwent surgery with stage I NSCLC between 2004 and 2013...
October 28, 2017: Clinical Lung Cancer
journal
journal
34772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"